Imbria
Founded 2018 · 16 employees on LinkedIn · 5 known investors
Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy. It focuses on therapies for patients with limited treatment options in cardiometabolic and cardiovascular conditions.
Founders & leadership
Investors · 5
In the news
Frequently asked questions
- What does Imbria do?
- Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy. It focuses on therapies for patients with limited treatment options in cardiometabolic and cardiovascular conditions.
- Who are Imbria's investors?
- Imbria's investors include AN Venture Partners, RA Capital, Sanofi Ventures, SV Health Investors, Catalio Capital Management.